Available from stock

Olaparib

SKU: O0144

Category: API's & Intermediates

Synonyms: AZD 2281 , Ku-0059436 , Lynparza , 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; 763113-22-0
CAS-Number: C₂₄H₂₃FN₄O₃
Molecular Formula: 434.47
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: Off-white to beige powder
Identity: 1H-NMR

Properties

Solvents: DMSO (20 mg/ml), DMF (10 mg/ml), ethanol (1 mg/ml)
Melting Point: 198-209° C

Documentation

Safety Data Sheet (SDS): CDX O0144 MSDS.pdf

Shipping: AMBIENT
Short Term Storage: +4°C
Long Term Storage: -20°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at -20°C.

Hazard statements: H301 - H360D
Precautionary statements: P202 - P264 - P280 - P301 + P310 - P405 - P501
GHS Symbol: GHS06+GHS08
Signal word: Danger
RIDADR: UN2811
Transportation: Packing Group III

Description: Olaparib is a cell-permable potent inhibitor of PARP1 and PARP2 (IC50=5 and 1nM, respectively) but is less effective against the PARP tankyrase-1 (IC50=1.5µM). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in base excision repair (BER), counteracting against DNA alkylating agents. Olaparib is a anticancer and chemotherapeutic agent (especially in cancers with BRCA mutations) that can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.
Smiles: O=C(C1CC1)N2CCN(C(C3=C(F)C=CC(CC(C4=C5C=CC=C4)=NNC5=O)=C3)=O)CC2
InChi Key: FDLYAMZZIXQODN-UHFFFAOYSA-N
References: (1) K.A. Menear, et al., J. Med. Chem. 51, 6581 (2008) , (2) S. Rottenberg, et al., PNAS 105, 17079 (2008) , (3) B.P. Rowe & P.M. Glazer, Breast Cancer Res. 12, 1 (2010) , (4) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011) , (5) R. Plummer, Breast Cancer Res. 13, 1 (2011) , (6) M. Javle & N.J. Curtin, Ther. Adv. Med. Oncol. 3, 257 (2011) , (7) D. Davar, et al., Curr. Med. Chem. 19, 3907 (2012) , (8) C.C. Gunderson & K.N. Moore, Future Oncol. 11, 747 (2015) , (9) F. De Felice, et al., Drug Des. Devel. Ther. 11, 547 (2017) , (10) J. Stewart, et al., Expert Rev. Anticancer Ther. 18, 947 (2018)

Olaparib is a cell-permable potent inhibitor of PARP1 and PARP2 (IC50=5 and 1nM, respectively) but is less effective against the PARP tankyrase-1 (IC50=1.5µM). Some poly(ADP-ribose) polymerases (PARPs) assist in the repair of single-strand DNA nicks, an important step in base excision repair (BER), counteracting against DNA alkylating agents. Olaparib is a anticancer and chemotherapeutic agent (especially in cancers with BRCA mutations) that can be used in cells and in animals, alone or in combination therapy with alkylating agents, to block BER and increase cancer cell death.

SKU: O0144 Category: API's & Intermediates

Additional information

Additional information

Synonyms	AZD 2281, Ku-0059436, Lynparza, 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
Purity	≥98% (HPLC)
Appearance	Off-white to beige powder
CAS-Number	763113-22-0
Molecular Formula	C24H23FN4O3
Molecular Weight	434.47
Identity	1H-NMR
Solvents	DMSO (20 mg/ml), DMF (10 mg/ml), ethanol (1 mg/ml)
Melting Point	198-209° C
Smiles	O=C(C1CC1)N2CCN(C(C3=C(F)C=CC(CC(C4=C5C=CC=C4)=NNC5=O)=C3)=O)CC2
InChi Key	FDLYAMZZIXQODN-UHFFFAOYSA-N
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at -20°C.
Hazard statements	H301 – H360D
Precautionary statements	P202 – P264 – P280 – P301 + P310 – P405 – P501
GHS Symbol	GHS06+GHS08
Signal word	Danger
RIDADR	UN2811
Transportation	Packing Group III
References	(1) K.A. Menear, et al., J. Med. Chem. 51, 6581 (2008), (2) S. Rottenberg, et al., PNAS 105, 17079 (2008), (3) B.P. Rowe & P.M. Glazer, Breast Cancer Res. 12, 1 (2010), (4) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011), (5) R. Plummer, Breast Cancer Res. 13, 1 (2011), (6) M. Javle & N.J. Curtin, Ther. Adv. Med. Oncol. 3, 257 (2011), (7) D. Davar, et al., Curr. Med. Chem. 19, 3907 (2012), (8) C.C. Gunderson & K.N. Moore, Future Oncol. 11, 747 (2015), (9) F. De Felice, et al., Drug Des. Devel. Ther. 11, 547 (2017), (10) J. Stewart, et al., Expert Rev. Anticancer Ther. 18, 947 (2018)
Quantity	100 mg, 1 g, Bulk